Australian Trial to Test Whether Cannabis Can Prevent Chemotherapy Gut Damage: Protocol Published

The CANCAN trial will be the first rigorous randomised controlled trial to test combined CBD and THC as a prophylactic strategy against gastrointestinal mucositis and its wider symptom cluster in cancer patients receiving mucotoxic chemotherapy, though no results are yet available from this protocol-stage publication.

Why This Matters

Chemotherapy-induced gastrointestinal mucositis is a painful, debilitating consequence of cancer treatment that affects a large proportion of patients receiving mucotoxic regimens, and no approved intervention currently exists to prevent it. The resulting symptom cascade, including nausea, appetite loss, pain, and fatigue, significantly undermines quality of life and treatment adherence. The endocannabinoid system’s involvement in gut inflammation, pain signaling, and appetite regulation provides a scientifically credible basis for investigating cannabinoid-based prevention. The publication of a rigorous trial protocol at this stage allows the research community to scrutinize the methodology before results emerge, a hallmark of transparent clinical science.

Clinical Summary

Gastrointestinal mucositis, the inflammatory breakdown of the gut lining caused by cytotoxic chemotherapy, remains one of the most common and undertreated complications in oncology. Despite decades of research into mucosal injury pathways, no pharmacological agent has been approved to prevent this condition or the secondary symptom cluster it drives. The CANCAN trial, described in a protocol published in BMJ Open by Hardy and colleagues, is a phase II, double-blind, placebo-controlled randomised trial designed to test whether daily sublingual wafers containing CBD (300 mg/day) plus self-titrated THC (5 to 20 mg/day) can reduce the burden of chemotherapy-induced GI mucositis. The mechanistic rationale rests on the endocannabinoid system’s known regulatory roles in gut inflammation, nociception, nausea, appetite, and mood, all domains severely disrupted by mucotoxic treatment.

Because this is a protocol publication, it reports no clinical outcomes, effect sizes, or safety data from the trial itself. The planned enrollment is 176 adults with solid or haematological cancers across four South Australian hospitals, with participants followed over three chemotherapy cycles. Design strengths include a tiered enrichment strategy that focuses resources on patients who develop mucositis, a pharmacokinetics sub-study, and electronic patient-reported outcome collection. The authors themselves acknowledge significant risks of participant dropout owing to daily questionnaire burden, driving restrictions associated with THC use, and the extended study duration. Results from the completed trial are required before any clinical recommendations regarding cannabinoid prophylaxis for mucositis can be considered.

Dr. Caplan’s Take

This is exactly the kind of trial the field needs, and I want to be clear about why. Patients undergoing mucotoxic chemotherapy regularly ask whether cannabis might help with their gut symptoms, nausea, and appetite loss. The honest answer right now is that we have mechanistic plausibility and fragmentary clinical signals, but no rigorous prophylactic evidence. The CANCAN protocol is well designed, with a meaningful primary outcome, a sensible dosing strategy that allows THC self-titration, and a pharmacokinetics component that will help us understand what is actually happening at the drug level. But a protocol is a plan, not a result. We cannot extrapolate from its existence to any conclusion about benefit.

In my practice, when patients on mucotoxic regimens ask about cannabis for GI protection specifically, I explain that we do not yet have evidence supporting prophylactic use for mucositis prevention. For symptom management of established nausea, pain, or appetite loss, the conversation is different and draws on a broader, if still imperfect, evidence base. I would not recommend initiating cannabinoid therapy solely to prevent mucositis based on what is currently available. If the CANCAN trial delivers positive results, that conversation changes substantially.

Clinical Perspective

This protocol occupies an early but important position in the research arc for cannabinoid-based mucositis prevention. It builds on established science regarding endocannabinoid system involvement in gut homeostasis and on preliminary phase II data suggesting benefit from combined CBD and THC in chemotherapy-induced nausea and graft-versus-host disease. However, these prior signals come from different clinical contexts and cannot be directly extrapolated to a prophylactic mucositis indication. The protocol itself, while methodologically transparent and well structured, provides no evidence that clinicians can use to support or refute the use of cannabinoids in this setting. Until results are published, patient-facing guidance should not reference this trial as supporting prophylactic cannabis use.

Clinicians should also be aware of practical considerations relevant to combined CBD and THC administration in oncology populations. CBD at 300 mg/day is a potent inhibitor of several cytochrome P450 enzymes, including CYP3A4 and CYP2C19, which raises the possibility of interactions with chemotherapeutic agents, antiemetics, and supportive care medications commonly used in these patients. THC self-titration introduces variability that may affect both tolerability and blinding integrity. For now, the single most actionable recommendation is to document patient interest in cannabinoid use for chemotherapy side effects and to revisit the evidence when CANCAN trial results become available, rather than acting on the protocol alone.

Study at a Glance

Study Type

Phase II, randomised, double-blind, placebo-controlled trial (protocol only; no results)

Population

Adults with solid or haematological cancers receiving mucotoxic chemotherapy (n=176 planned)

Intervention

CBD 300 mg/day plus THC 5 to 20 mg/day (self-titrated), sublingual wafer

Comparator

Matched placebo sublingual wafer

Primary Outcome

GI mucositis burden measured by the Mucositis Daily Questionnaire

Sample Size

176 participants planned across four sites

Setting

Four tertiary hospitals in South Australia

Duration

Three chemotherapy cycles per participant

Journal

BMJ Open

Year

2024

Registration

ACTRN12622000419763

Funding Source

Not specified in extracted data

What Kind of Evidence Is This

This is a pre-results trial protocol published in a peer-reviewed journal, not a study reporting clinical outcomes. In the evidence hierarchy, protocol publications sit below even preliminary results papers because they contain no patient data, effect estimates, or safety observations. Their value lies entirely in methodological transparency: they allow independent evaluation of trial design, reduce the risk of outcome reporting bias, and establish a public record of the researchers’ intentions before data collection is complete. The single most important inference constraint is that nothing in this document can support or refute the efficacy of the intervention.

How This Fits With the Broader Literature

The CANCAN trial builds on a growing body of preclinical and early clinical research implicating the endocannabinoid system in gastrointestinal homeostasis and inflammatory modulation. Prior phase II work has suggested potential benefits of combined CBD and THC for chemotherapy-induced nausea and vomiting, and separate investigations have explored cannabinoid effects in graft-versus-host disease, where mucosal injury is also central. However, none of these prior studies have examined prophylactic cannabinoid use specifically targeting GI mucositis as a primary outcome in the chemotherapy setting. The CANCAN protocol therefore represents an extension of existing mechanistic knowledge into a novel therapeutic context rather than a confirmation or contradiction of established clinical evidence.

Common Misreadings

The most likely overinterpretation is treating the publication of this protocol as evidence that cannabis prevents or treats chemotherapy-induced gut damage. Protocol publications generate attention, particularly in the cannabinoid space, and the detailed mechanistic rationale presented here may be mistaken for demonstrated clinical benefit. It is essential to recognize that no patient has yet been reported on, no outcomes have been measured, and the hypotheses remain entirely untested within this trial framework. Citing this paper as support for clinical use of CBD and THC in mucositis prevention would fundamentally exceed what the evidence provides.

Bottom Line

The CANCAN trial protocol describes a well-designed phase II RCT that will test whether combined CBD and THC can prevent chemotherapy-induced gastrointestinal mucositis. It contributes methodological transparency and a clear mechanistic rationale to the field, but it contains no efficacy or safety data. Clinical practice should not change based on this publication. The trial’s results, when available, will determine whether this intervention merits further investigation or clinical consideration.

References

1. Hardy J, et al. CANnabinoids for the prevention and treatment of chemotherapy-induced gastrointestinal mucositis and its associated symptom cluster in people with CANcer (CANCAN): a randomised, double-blind, placebo-controlled, phase II trial protocol. BMJ Open. 2024. Trial registration: ACTRN12622000419763.